BNP/CALL/ASTRAZENECA/13000/0.1/20.06.25 | Market Closed - Börse Stuttgart 01:42:59 31/05/2024 pm IST | ||
| 1.2 EUR | +2.56% |
|
| Current month | +1.69% | ||
| 1 month | +1.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 1.2 | +2.56% |
| 30/24/30 | 1.17 | -0.85% |
| 29/24/29 | 1.18 | -7.81% |
| 28/24/28 | 1.28 | -5.88% |
| 24/24/24 | 1.36 | -2.16% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 01:42 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC8HB6 |
| ISIN | DE000PC8HB68 |
| Date issued | 17/04/2024 |
| Strike | 13,000 p |
| Maturity | 20/06/2025 (384 Days) |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.4 € |
|---|---|
| Lowest since issue | 0.64 € |
| Spread | 0.01 € |
| Spread % | 0.78% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Warrants
- Warrant
